Sanofi SA and Regeneron report positive top-line results from nine phase 3 trials of Alirocumab in People with Hypercholesterolemia


Wednesday, 30 Jul 2014 08:00am EDT 

Sanofi SA and Regeneron Pharmaceuticals Inc:Says nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator.Trial met its primary efficacy endpoint of a greater percent reduction from baseline in LDL-C at 24 weeks with alirocumab compared to ezetimibe. 

Company Quote

74.99
-0.65 -0.86%
24 Dec 2014